Vigil Neuroscience price target lowered to $16 from $17 at Guggenheim

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Vigil Neuroscience to $16 from $17 and keeps a Buy rating on the shares. With several potential catalysts coming over the next 6-10 months, Guggenheim expects Vigil to become much more of a focus in the neuroimmunology space, and as the only company that has two TREM2 modalities, could become a leading player in the space, the analyst tells investors in a research note.